Skip Navigation LinksHome > November 2011 - Volume 118 - Issue 5 > Fetal and Neonatal Alloimmune Thrombocytopenia: A Management...

ACOG MEMBER SUBSCRIPTION ACCESS

If you are an ACOG Fellow and have not logged in or registered to Obstetrics & Gynecology, please follow these step-by-step instructions to access journal content with your member subscription.

Obstetrics & Gynecology:
doi: 10.1097/AOG.0b013e31823403f4
Current Commentary

Fetal and Neonatal Alloimmune Thrombocytopenia: A Management Algorithm Based on Risk Stratification

Pacheco, Luis D. MD; Berkowitz, Richard L. MD; Moise, Kenneth J. Jr MD; Bussel, James B. MD; McFarland, Janice G. MD; Saade, George R. MD

Collapse Box

Abstract

Fetal and neonatal alloimmune thrombocytopenia constitutes the most common cause of severe thrombocytopenia in fetuses and neonates and of intracranial hemorrhage among term newborns. The cornerstone of therapy involves the use of steroids and intravenous immunoglobulins. Despite the risk of potentially devastating consequences to the fetus, fetal blood sampling has typically been used to document response to therapy. We propose a therapeutic algorithm based on risk stratification with individualized treatment optimization without the use of fetal blood sampling.

© 2011 The American College of Obstetricians and Gynecologists

Login

ACOG MEMBER SUBSCRIPTION ACCESS

If you are an ACOG Fellow and have not logged in or registered to Obstetrics & Gynecology, please follow these step-by-step instructions to access journal content with your member subscription.

Article Tools

Share